Major Shareholder NEA 15 Agrees to Tender 5.3% Stake in Arcellx Acquisition by Gilead Sciences

summarizeSummary

Major institutional investor New Enterprise Associates 15 (NEA 15) has formally agreed to tender its 5.3% stake in Arcellx, Inc. as part of the acquisition by Gilead Sciences, Inc.

check_boxKey Events

• Major Shareholder Support for Acquisition

  New Enterprise Associates 15 (NEA 15), a significant institutional investor, has filed an amended Schedule 13D confirming its agreement to tender its 5.3% stake in Arcellx, Inc.

• Commitment to Gilead Sciences Merger

  NEA 15 has entered into a tender and support agreement, committing to tender all 3,045,262 shares in connection with the previously announced acquisition by Gilead Sciences, Inc.

• Reinforces Merger Completion

  This formal commitment from a major shareholder strengthens the likelihood of the successful completion of the acquisition, which offers $115.00 per share in cash plus a contingent value right.

auto_awesomeAnalysis

This Schedule 13D/A confirms that New Enterprise Associates 15 (NEA 15), a significant institutional investor holding 5.3% of Arcellx's common stock, has formally entered into a tender and support agreement. This agreement commits NEA 15 to tender all its shares in connection with the previously announced acquisition of Arcellx by Gilead Sciences, Inc. for $115.00 per share in cash plus a contingent value right. This filing reinforces the likelihood of the merger's successful completion by demonstrating strong institutional shareholder alignment with the acquisition terms. The stock is currently trading near its 52-week high, reflecting the market's positive response to the acquisition offer.